Home institutional buyers (DIIs) maintained their robust shopping for spree in Indian equities by way of June 2025, with web inflows reaching Rs. 69,176.47 crore as of June 27. This marks the second-highest month-to-month influx by DIIs up to now this yr, reflecting continued confidence available in the market.
That stated, on twenty seventh June, DIIs turned web sellers, pulling out round Rs. 588.93 crore, primarily based on provisional knowledge from the exchanges. Nevertheless, this was possible a short pause after a month of sustained shopping for.
Among the many many shares that noticed elevated DII curiosity in June 2025, listed here are two firms the place institutional buyers elevated their stake:
With a market cap of Rs. 2,042.6 crores, the inventory moved up by almost 1 p.c on BSE, rising to Rs. 176.15 on Friday. Home institutional buyers (DIIs) holdings have grown to 2.65 p.c in June 2025, up by 0.8 p.c from 1.85 p.c in March 2025 and by 0.1 p.c from 2.55 p.c in June 2024.
In This autumn FY25, Ugro Capital has witnessed a progress of almost 25 p.c YoY in income from operations to Rs. 403 crores, accompanied by a web revenue progress of round 24 p.c YoY to Rs. 41 crores.
UGRO Capital Restricted, a non-deposit taking Non-Banking Monetary Firm (NBFC-ND), is engaged within the enterprise of lending and primarily offers in financing the MSME sector with a concentrate on healthcare, training, chemical substances, meals processing/FMCG, hospitality, electrical gear & elements, auto elements, micro enterprises and lightweight engineering.
With a market cap of Rs. 50,510.5 crores, the inventory moved up by almost 1.3 p.c on BSE, rising to Rs. 379.3 on Friday. DII holdings have grown to 21.45 p.c in June 2025, up by 5.72 p.c from 15.73 p.c in March 2025 and by 7.16 p.c from 14.29 p.c in June 2024.
In This autumn FY25, Biocon has witnessed a progress of almost 13 p.c YoY in income from operations to Rs. 4,417 crores, accompanied by a web revenue progress of round 106 p.c YoY to Rs. 459 crores.
Biocon Restricted is engaged within the enterprise of producing and providing biotechnology merchandise and analysis providers. It’s an innovation-led international biopharmaceutical firm dedicated to enhancing inexpensive entry to advanced therapies for persistent circumstances like diabetes, most cancers, and autoimmune illnesses.
Written by Shivani Singh
Disclaimer
The views and funding suggestions expressed by funding specialists/broking homes/score companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of economic losses. Traders should subsequently train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Non-public Restricted or the writer will not be responsible for any losses induced because of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
